MCID: HMR003
MIFTS: 59

Hemorrhagic Disease

Categories: Blood diseases, Immune diseases, Rare diseases

Aliases & Classifications for Hemorrhagic Disease

MalaCards integrated aliases for Hemorrhagic Disease:

Name: Hemorrhagic Disease 12 15
Hemorrhagic Disorders 45 74
Hemorrhagic Diathesis 12
Hemorrhagic Diseases 56
Bleeding Tendency 74

Classifications:



External Ids:

Disease Ontology 12 DOID:2213
ICD9CM 36 287.9
MeSH 45 D006474
ICD10 34 D68.3 D69.9

Summaries for Hemorrhagic Disease

MalaCards based summary : Hemorrhagic Disease, also known as hemorrhagic disorders, is related to alpha-2-plasmin inhibitor deficiency and von willebrand disease, type 1, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Hemorrhagic Disease is F11 (Coagulation Factor XI), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Collagen chain trimerization. The drugs Warfarin and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include bone, t cells and bone marrow, and related phenotypes are Synthetic lethal with vaccinia virus (VACV) infection and homeostasis/metabolism

Related Diseases for Hemorrhagic Disease

Diseases in the Hemorrhagic Disease family:

Hemorrhagic Disease Due to Alpha-1-Antitrypsin Pittsburgh Mutation

Diseases related to Hemorrhagic Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 236)
# Related Disease Score Top Affiliating Genes
1 alpha-2-plasmin inhibitor deficiency 31.4 F2 SERPINC1 SERPINF2
2 von willebrand disease, type 1 31.3 F2 F3 F8 VWF
3 factor v deficiency 31.1 F10 F11 F2 F3 F5 F7
4 factor vii deficiency 30.9 F10 F2 F3 F7 F8 F9
5 von willebrand disease, type 3 30.8 F11 F3 F8 GP1BA VWF
6 von willebrand disease, type 2 30.8 F3 F7 F8 GP1BA VWF
7 factor xi deficiency 30.6 F11 F2 F3 F9 SERPINC1 THBD
8 qualitative platelet defect 30.1 F2 F3 VWF
9 factor x deficiency 30.0 F10 F11 F2 F3 F5 F7
10 nodular nonsuppurative panniculitis 30.0 F8 SERPINA1 SERPINF2
11 thrombocytosis 29.8 F2 F3 SERPINC1
12 placental abruption 29.7 F2 F5 SERPINC1 THBD
13 factor xii deficiency 29.6 F3 F5 F9 SERPINC1
14 acute promyelocytic leukemia 29.6 F3 SERPINC1 SERPINF2 THBD
15 thrombotic thrombocytopenic purpura 29.3 F3 THBD VWF
16 dysfibrinogenemia 29.3 F2 F5 PLAT SERPINC1 THBD
17 hemophilia 29.2 F2 F3 F7 F8 F9 VWF
18 hemarthrosis 29.1 F10 F7 F8 F9 VWF
19 acquired hemophilia a 29.1 F11 F3 F5 F8 F9
20 purpura 29.1 F2 F3 SERPINC1 THBD VWF
21 hemophilia b 28.9 F10 F11 F2 F3 F7 F8
22 acquired hemophilia 28.9 F10 F11 F3 F5 F8 F9
23 blood platelet disease 28.8 F10 F2 F3 F8 GP1BA SERPINC1
24 thrombophilia due to activated protein c resistance 28.7 F10 F2 F3 F5 F8 F9
25 hemophilia a 28.3 F10 F11 F3 F5 F7 F8
26 von willebrand's disease 28.0 F11 F2 F3 F5 F8 F9
27 disseminated intravascular coagulation 26.7 F2 F3 F5 F7 F9 PLAT
28 thrombosis 26.1 F10 F2 F3 F5 F7 F8
29 antithrombin, familial hemorrhagic diathesis due to 12.3
30 hemorrhagic disease due to alpha-1-antitrypsin pittsburgh mutation 12.0
31 hermansky-pudlak syndrome 11.7
32 hermansky-pudlak syndrome 1 11.5
33 hermansky-pudlak syndrome 2 11.4
34 hermansky-pudlak syndrome 3 11.4
35 hermansky-pudlak syndrome 4 11.4
36 hermansky-pudlak syndrome 5 11.4
37 hermansky-pudlak syndrome 6 11.4
38 hermansky-pudlak syndrome 7 11.4
39 hermansky-pudlak syndrome 8 11.4
40 hermansky-pudlak syndrome 9 11.4
41 vitamin k deficiency bleeding 11.3
42 lujo hemorrhagic fever 10.8
43 scott syndrome 10.8
44 bleeding disorder, platelet-type, 8 10.8
45 splenic disease 10.5 F2 F3
46 vascular hemostatic disease 10.5 F2 F3
47 congenital disorder of glycosylation, type iii 10.4 SERPINA1 SERPINC1
48 esophageal varix 10.4 F2 SERPINC1
49 mesenteric vascular occlusion 10.3 F2 F7
50 cerebral falx meningioma 10.3 F2 F3

Comorbidity relations with Hemorrhagic Disease via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Deficiency Anemia Familial Atrial Fibrillation
Heart Disease

Graphical network of the top 20 diseases related to Hemorrhagic Disease:



Diseases related to Hemorrhagic Disease

Symptoms & Phenotypes for Hemorrhagic Disease

UMLS symptoms related to Hemorrhagic Disease:


angina pectoris, edema, chest pain, abnormal bruising

GenomeRNAi Phenotypes related to Hemorrhagic Disease according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with vaccinia virus (VACV) infection GR00362-A 9.02 SERPINA1 SERPINC1 SERPINE1 SERPINF2 THBD

MGI Mouse Phenotypes related to Hemorrhagic Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.2 F10 F11 F2 F3 F5 F7
2 cardiovascular system MP:0005385 10.18 F10 F11 F2 F3 F5 F7
3 hematopoietic system MP:0005397 10.11 F11 F2 F3 F8 F9 GP1BA
4 immune system MP:0005387 9.96 F11 F2 F3 F8 F9 PLAT
5 mortality/aging MP:0010768 9.77 F10 F11 F2 F3 F5 F7
6 liver/biliary system MP:0005370 9.63 F11 F5 F9 SERPINC1 SERPINE1 THBD
7 respiratory system MP:0005388 9.1 F11 F2 F3 PLAT SERPINE1 THBD

Drugs & Therapeutics for Hemorrhagic Disease

Drugs for Hemorrhagic Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 927)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Warfarin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 81-81-2 6691 54678486
2
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53-03-2 5865
3
Melphalan Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 148-82-3 460612 4053
4
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 179324-69-7 387447 93860
5
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 1177-87-3
6
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 50-02-2 5743
7
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
8
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
9
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 23214-92-8 31703
10
Zoledronic Acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 118072-93-8 68740
11
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1401-55-4
12
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
13
Thrombin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable
14
Anti-inhibitor coagulant complex Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable
15
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
16
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978
17
Hydroxychloroquine Approved Phase 4,Phase 1,Phase 2 118-42-3 3652
18
Azathioprine Approved Phase 4,Phase 3,Phase 2,Not Applicable 446-86-6 2265
19
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 104987-11-3 445643 439492 6473866
20
Tranexamic Acid Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1197-18-8 5526
21
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
22
Lenalidomide Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 191732-72-6 216326
23
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 2921-57-5
24
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 302-25-0
25
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-24-8 5755
26
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 83-43-2 6741
27
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
28
Clarithromycin Approved Phase 4,Phase 2,Phase 3,Phase 1 81103-11-9 84029
29
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
30
Amoxicillin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 26787-78-0 33613
31
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
32
Heparin Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 9005-49-6 772 46507594
33
Dalteparin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6
34
Atorvastatin Approved Phase 4,Phase 2,Phase 1 134523-00-5 60823
35
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 33419-42-0 36462
36
Cytarabine Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 147-94-4, 65-46-3 6253
37
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 216974-75-3
38
Apixaban Approved Phase 4,Phase 3,Phase 2,Not Applicable 503612-47-3 10182969
39
Iron Approved, Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6, 15438-31-0 23925 27284
40 Daratumumab Approved Phase 4,Phase 2,Phase 3,Phase 1 945721-28-8
41
Phylloquinone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 84-80-0
42
Phenindione Approved, Investigational Phase 4 83-12-5 4760
43 fluindione Approved, Investigational Phase 4 957-56-2
44
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
45
Hydroxyurea Approved Phase 4,Phase 3,Phase 2,Not Applicable 127-07-1 3657
46
Anagrelide Approved Phase 4,Phase 3,Phase 2 68475-42-3 2182
47
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 1,Phase 2,Not Applicable 9004-61-9 53477741
48
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
49
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Early Phase 1 124-94-7 31307
50
Mesna Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 3375-50-6 598

Interventional clinical trials:

(show top 50) (show all 3935)
# Name Status NCT ID Phase Drugs
1 Activates Charcoal for Patients Undergoing Invasive Procedure Delayed Due to Direct Oral Anticoagulants Unknown status NCT02969746 Phase 4 Activated Charcoal
2 Clinical and Economic Implications of Genetic Testing for Warfarin Management Unknown status NCT00964353 Phase 4 Warfarin
3 The Effect of Human Albumin on Coagulation Competence and Hemorrhage Unknown status NCT02270723 Phase 4 5% Human Albumin " Behring";Lactated Ringer
4 A Clinical Phenotype Based Individualized Prophylaxis in Chinese Hemophilia A Children Unknown status NCT02999308 Phase 4
5 Subclinical Joint Bleeding in Irish Adults With Severe Haemophilia A on Personalised Prophylaxis Regimens Unknown status NCT02314325 Phase 4 ADVATE [Antihemophilic Factor (Recombinant)];ADVATE [Antihemophilic Factor (Recombinant)]
6 Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma Unknown status NCT02773550 Phase 4 Bortezomib;Melphalan;Prednisone
7 Caffeic Acid Combining High-dose Dexamethasone in Management of ITP Unknown status NCT02556814 Phase 4 Caffeic acid tablets;Dexamethasone;placebo
8 Trial of HoLEP vs. PVP in Treating BPH in Patients With Bleeding Tendency Unknown status NCT02293759 Phase 4
9 A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma Unknown status NCT01868828 Phase 4 PAD;VCD
10 Study Using Plasma for Patients Requiring Emergency Surgery Unknown status NCT01221389 Phase 4 Human Plasma
11 Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma Unknown status NCT01249690 Phase 4 Bortezomib,Pirarubicin,Dexamethasone;Thalidomide,Pirarubicin,Dexamethasone
12 Stage I Multiple Myeloma Treatment Unknown status NCT00733538 Phase 4 zometa
13 Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) Completed NCT01558739 Phase 4 INC424
14 Effect of Colloid Versus Crystalloid on Coagulation in Elective Urological Surgery Completed NCT02009033 Phase 4 Lactated Ringer;Hydroxyethylstarch
15 Anticoagulant Clinics and Vitamin K Antagonists Completed NCT00966290 Phase 4 Anticoagulant (warfarin, acenocoumarol, fluindione);Anticoagulant (warfarin, acenocoumarol, fluindione)
16 Comparison of Three Management Strategies for Post Cardiac Surgery Bleeding Completed NCT00188747 Phase 4
17 Octaplas Pediatric Plasma Replacement Trial Completed NCT02050841 Phase 4
18 Fibrinogen for Treatment of Pediatric Dilutional Coagulopathy. FibPaed Study. Completed NCT01487837 Phase 4 Human fibrinogen concentrate
19 BAY14-2222 Prophylaxis and Joint Function Improvement (Adults) Completed NCT00586521 Phase 4 Kogenate (BAY14-2222)
20 Comparison of Different Prophylaxis Regimens for Moderate to Severe Hemophilia A Pediatric Patients Completed NCT02727647 Phase 4 FVIII;FVIII
21 Efficacy and Cost Effectiveness of Pharmacokinetic Dosing in Haemophilia A Completed NCT02697370 Phase 4 Pharmacokinetic based dosage change
22 PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A Completed NCT02492984 Phase 4 Intravenous infusions of Xyntha
23 China ADVATE PTP Study Completed NCT02170402 Phase 4
24 Prophylaxis Versus on Demand Treatment for Children With Hemophilia A Completed NCT01810666 Phase 4
25 Clinical Pharmacokinetics Study of ART-123 in Disseminated Intravascular Coagulation (DIC) Subjects With Renal Impairment Completed NCT01704001 Phase 4 ART-123
26 Fibrinogen as an Alternative to FFP in Aortic Surgery. Completed NCT00994045 Phase 4
27 Canadian Hemophilia Prophylaxis Study Completed NCT01085344 Phase 4
28 Survey of Inhibitors in Plasma-Product Exposed Toddlers Completed NCT01064284 Phase 4 PLASMA DERIVED Factor VIII;Recombinant FVIII
29 Study of Safety And Efficacy Of ReFacto AF In Previously Untreated Hemophilia A Patients In The Usual Care Setting Completed NCT00950170 Phase 4
30 Joint Status in Subjects With Severe Hemophilia A in Relation to Different Treatment Regimens Completed NCT00927667 Phase 4
31 Pharmacokinetic Study of ADVATE 3000 IU in Previously Treated Patients With Severe Hemophilia A Completed NCT00916032 Phase 4
32 Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients Completed NCT00914459 Phase 4
33 Pharmacokinetic Comparison of Advate rAHF-PFM With Recombinate rAHF in Patients With Severe Hemophilia A Completed NCT00666406 Phase 4 Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method (rAHF-PFM);Recombinant Factor VIII (rAHF)
34 Russian Kogenate Pediatric Study Completed NCT00632814 Phase 4 rFVIII-FS (Kogenate FS, BAY14-2222) 70 IU/kg, dosing once per week;rFVIII-FS (Kogenate FS, BAY14-2222), 70 IU/kg twice per week (30 IU/kg + 40 IU/kg);rFVIII-FS (Kogenate FS, BAY14-2222) 75 IU/kg, dosing three times per week (3 x 25 IU/kg)
35 Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery Completed NCT00357656 Phase 4 Recombinant Protein-Free Factor VIII (rAHF-PFM);Recombinant Protein-Free Factor VIII (rAHF-PFM)
36 Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A Completed NCT00289536 Phase 4
37 Combination Therapy of Low Doses of rFVIIa and FEIBA for Severe Hemophilia A Patients With an Inhibitor to Factor VIII Completed NCT00284193 Phase 4 rFVIIa-FEIBA therapy for hemophilia A inhibitors;FEIBA- Activated Prothrombin Complexes
38 Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A Completed NCT00243386 Phase 4 Antihemophilic factor, recombinant, manufactured protein-free;Antihemophilic factor, recombinant, manufactured protein-free
39 Study Evaluating ReFacto® in Hemophilia A Undergoing Major Surgery Completed NCT00092976 Phase 4 ReFacto
40 A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients Completed NCT00202644 Phase 4 Anagrelide;Hydroxyurea
41 Early Administration of Fibrinogen in Polytraumatized Patients With Hypofibrinogenemia: a Randomized Feasibility Trial Completed NCT02864875 Phase 4 Fibrinogen concentrate
42 Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery Completed NCT01561391 Phase 4 activated recombinant human factor VII;activated recombinant human factor VII;factor VIII
43 Safety and Efficacy of Benefix in Patients With Hemophilia B in Usual Care Settings in China Completed NCT02336178 Phase 4 Benefix
44 The Study of Different Dose Rituximab in the Treatment of ITP Completed NCT03258866 Phase 4 Rituximab;Rituximab
45 Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia Completed NCT03229746 Phase 4 Hydroxychloroquine;vincristine;azathioprine
46 Tacrolimus in Children With Henoch-Schönlein Purpura Nephritis Completed NCT03222687 Phase 4 tacrolimus;prednisone
47 Study of Voncento® in Subjects With Von Willebrand Disease Completed NCT02552576 Phase 4
48 A Comparison Study of Bypassing Agent Therapy With and Without Tranexamic Acid in Haemophilia A Patients With Inhibitor Completed NCT01800435 Phase 4 aPCC, aPCC + TXA;rFVIIa, rFVIIa + TXA
49 A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma Completed NCT02268890 Phase 4 Bortezomib
50 Severe Aortic Stenosis and Acquired Von Willebrand´s Disease: The Impact of Desmopressin in Valve-Replacement Surgery Completed NCT01994330 Phase 4 desmopressin

Search NIH Clinical Center for Hemorrhagic Disease

Cochrane evidence based reviews: hemorrhagic disorders

Genetic Tests for Hemorrhagic Disease

Anatomical Context for Hemorrhagic Disease

MalaCards organs/tissues related to Hemorrhagic Disease:

42
Bone, T Cells, Bone Marrow, B Cells, Testes, Myeloid, Kidney

Publications for Hemorrhagic Disease

Articles related to Hemorrhagic Disease:

(show top 50) (show all 554)
# Title Authors Year
1
GI.1b/GI.1b/GI.2 recombinant rabbit hemorrhagic disease virus 2 (Lagovirus europaeus/GI.2) in Morocco, Africa. ( 30284631 )
2019
2
Crude extracts of recombinant baculovirus expressing rabbit hemorrhagic disease virus 2 VLPs from both insect and rabbit cells protect rabbits from rabbit hemorrhagic disease caused by RHDV2. ( 30291504 )
2019
3
Identification and characterization of epizootic hemorrhagic disease virus serotype 6 in cattle co-infected with bluetongue virus in Trinidad, West Indies. ( 30642583 )
2019
4
Bluetongue and epizootic hemorrhagic disease viruses: recent developments with these globally re-emerging arboviral infections of ruminants. ( 30654271 )
2019
5
Bluetongue virus and epizootic hemorrhagic disease virus survey in cattle of the Galapagos Islands. ( 30661471 )
2019
6
Structure-function relationship in the 'termination upstream ribosomal binding site' of the calicivirus rabbit hemorrhagic disease virus. ( 30668745 )
2019
7
Adjuvant effects of interleukin-2 co-expression with VP60 in an oral vaccine delivered by attenuated Salmonella typhimurium against rabbit hemorrhagic disease. ( 30827404 )
2019
8
Clinicopathologic findings of naturally occurring Rabbit Hemorrhagic Disease Virus 2 infection in pet rabbits. ( 30861586 )
2019
9
Epizootic Hemorrhagic Disease in White-Tailed Deer, Canada. ( 30882321 )
2019
10
Detection of Epizootic Hemorrhagic Disease Virus Serotype 1, Israel. ( 30882324 )
2019
11
Complete Genome Sequence of <i>Epizootic hemorrhagic disease virus</i> Serotype 6, Isolated from Florida White-Tailed Deer (Odocoileus virginianus). ( 29622607 )
2018
12
Conventional and real time RT-PCR assays for the detection and differentiation of variant rabbit hemorrhagic disease virus (RHDVb) and its recombinants. ( 29024672 )
2018
13
Epizootic Hemorrhagic Disease Virus Serotype 6 Infection in Cattle, Japan, 2015. ( 29664367 )
2018
14
Hematologic Parameters and Viral Status for Zika, Chikungunya, Bluetongue, and Epizootic Hemorrhagic Disease in White-tailed Deer ( Odocoileus virginianus) on St John, US Virgin Islands. ( 29792759 )
2018
15
Adenoviral hemorrhagic disease in California mule deer, 1990-2014. ( 29582709 )
2018
16
Detection and Circulation of a Novel Rabbit Hemorrhagic Disease Virus in Australia. ( 29260677 )
2018
17
Novel subunit vaccine based on grass carp reovirus VP35 protein provides protective immunity against grass carp hemorrhagic disease. ( 29408645 )
2018
18
Recombinant canine adenovirus type 2 expressing rabbit hemorrhagic disease virus VP60 protein provided protection against RHD in rabbits. ( 29291998 )
2018
19
An Outbreak of Rabbit Hemorrhagic Disease in Finland. ( 29889007 )
2018
20
Extended genotypic evaluation and comparison of twenty-two cases of lethal EEHV1 hemorrhagic disease in wild and captive Asian elephants in India. ( 30133540 )
2018
21
Restricted Host Specificity of Rabbit Hemorrhagic Disease Virus Is Supported by Challenge Experiments in Immune-compromised Mice ( Mus musculus). ( 30161016 )
2018
22
Cluster analysis of hemorrhagic disease in Missouri's white-tailed deer population: 1980-2013. ( 30217140 )
2018
23
Detection of Rabbit Hemorrhagic Disease Virus GI.2/RHDV2/B in the Mediterranean Pine Vole ( Microtus duodecimcostatus) and White-Toothed Shrew ( Crocidura russula). ( 30226801 )
2018
24
Robust Innate Immunity of Young Rabbits Mediates Resistance to Rabbit Hemorrhagic Disease Caused by Lagovirus Europaeus GI.1 But Not GI.2. ( 30235853 )
2018
25
GENETIC RELATEDNESS OF EPIZOOTIC HEMORRHAGIC DISEASE VIRUS SEROTYPE 2 FROM 2012 OUTBREAK IN THE USA. ( 30284951 )
2018
26
Nucleolin mediates the internalization of rabbit hemorrhagic disease virus through clathrin-dependent endocytosis. ( 30339712 )
2018
27
Rabbit Hemorrhagic Disease Virus Non-structural Protein 6 Induces Apoptosis in Rabbit Kidney Cells. ( 30687286 )
2018
28
Hemorrhagic disorders of fibrinolysis: a clinical review. ( 29847021 )
2018
29
An update on the rabbit hemorrhagic disease virus (RHDV) strains circulating in Portugal in the 1990s: earliest detection of G3-G5 and G6. ( 28299483 )
2017
30
Virus Isolation and Molecular Detection of Bluetongue and Epizootic Hemorrhagic Disease Viruses from Naturally Infected White-Tailed Deer (Odocoileus virginianus). ( 28742422 )
2017
31
Epizootic hemorrhagic disease virus serotype 6 outbreak in Israeli cattle in 2015. ( 28803510 )
2017
32
Emergence of new virulent rabbit hemorrhagic disease virus strains in Saudi Arabia. ( 27913973 )
2017
33
Genomic Sequences of Epizootic Hemorrhagic Disease Viruses Isolated from Florida White-Tailed Deer. ( 29074661 )
2017
34
The First 10 Years (2006-15) of Epizootic Hemorrhagic Disease Virus Serotype 6 in the USA. ( 28657859 )
2017
35
Characterization of genome segments 2, 3 and 6 of epizootic hemorrhagic disease virus strains isolated in Japan in 1985-2013: Identification of their serotypes and geographical genetic types. ( 28506840 )
2017
36
Inclusion of an Arg-Gly-Asp receptor-recognition motif into the capsid protein of rabbit hemorrhagic disease virus enables culture of the virus in vitro. ( 28381555 )
2017
37
Binding of rabbit hemorrhagic disease virus-like particles to host histo-blood group antigens is blocked by antisera from experimentally vaccinated rabbits. ( 28780630 )
2017
38
Recombination between G2 and G6 strains of rabbit hemorrhagic disease virus (RHDV) in China. ( 27664029 )
2017
39
Dynamics of epizootic hemorrhagic disease virus infection within the vector, Culicoides sonorensis (Diptera: Ceratopogonidae). ( 29176848 )
2017
40
Adaptive diversification between the classic rabbit hemorrhagic disease virus (RHDV) and the RHDVa isolates: A genome-wide perspective. ( 28743597 )
2017
41
Rabbit haemorrhagic disease virus 2 (GI.2) is replacing endemic strains of RHDV in the Australian landscape within 18 months of its arrival. ( 29093089 )
2017
42
Evaluation of the efficiency under current use of human fibrinogen concentrate in trauma patients with life-threatening hemorrhagic disorders. ( 27254440 )
2017
43
Identification of novel rabbit hemorrhagic disease virus B-cell epitopes and their interaction with host histo-blood group antigens. ( 26612210 )
2016
44
A new variant of rabbit hemorrhagic disease virus G2-like strain isolated in China. ( 26827930 )
2016
45
Molecular evolution of epizootic hemorrhagic disease viruses in North America based on historical isolates using motif fingerprints. ( 27107856 )
2016
46
Generation of virus like particles for epizootic hemorrhagic disease virus. ( 27473984 )
2016
47
Rabbit hemorrhagic disease virus capsid, a versatile platform for foreign B-cell epitope display inducing protective humoral immune responses. ( 27549017 )
2016
48
Host and Potential Vector Susceptibility to an Emerging Orbivirus in the United States: Epizootic Hemorrhagic Disease Virus Serotype 6. ( 26459518 )
2016
49
Self-assembly of virus-like particles of rabbit hemorrhagic disease virus capsid protein expressed in Escherichia coli and their immunogenicity in rabbits. ( 27118636 )
2016
50
Innocuity of a commercial live attenuated vaccine for epizootic hemorrhagic disease virus serotype 2 in late-term pregnant cows. ( 26876438 )
2016

Variations for Hemorrhagic Disease

Expression for Hemorrhagic Disease

Search GEO for disease gene expression data for Hemorrhagic Disease.

Pathways for Hemorrhagic Disease

Pathways related to Hemorrhagic Disease according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.14 F10 F11 F2 F3 F5 F7
2
Show member pathways
12.68 F10 F11 F2 F3 F5 F7
3
Show member pathways
12.07 F2 F7 PLAT SERPINE1
4 11.97 F10 F11 F2 F3 F5 F7
5
Show member pathways
11.74 F10 F2 F7 F9
6
Show member pathways
11.7 F10 F11 F2 F3 F5 F7
7 11.69 F3 SERPINE1 THBD
8
Show member pathways
11.64 F2 GP1BA VWF
9 10.8 F10 F2 F7 F9
10 10.66 PLAT SERPINE1 SERPINF2
11 10.61 GP1BA VWF
12 10.46 GP1BA VWF

GO Terms for Hemorrhagic Disease

Cellular components related to Hemorrhagic Disease according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.92 F3 GP1BA PLAT SERPINF2 THBD
2 collagen-containing extracellular matrix GO:0062023 9.87 F3 PLAT SERPINA1 SERPINC1 SERPINE1 SERPINF2
3 endoplasmic reticulum lumen GO:0005788 9.86 F10 F2 F5 F7 F8 F9
4 extracellular region GO:0005576 9.8 F10 F11 F2 F3 F5 F7
5 blood microparticle GO:0072562 9.72 F2 SERPINC1 SERPINF2
6 Golgi lumen GO:0005796 9.71 F10 F2 F7 F9
7 endoplasmic reticulum-Golgi intermediate compartment membrane GO:0033116 9.69 F5 F8 SERPINA1
8 COPII-coated ER to Golgi transport vesicle GO:0030134 9.65 F5 F8 SERPINA1
9 platelet alpha granule lumen GO:0031093 9.63 F5 F8 SERPINA1 SERPINE1 SERPINF2 VWF
10 platelet alpha granule GO:0031091 9.54 F5 VWF
11 extracellular space GO:0005615 9.5 F10 F11 F2 F3 F5 F7
12 intrinsic component of external side of plasma membrane GO:0031233 9.49 F10 F3
13 serine-type peptidase complex GO:1905286 9.43 F3 F7
14 plasma membrane GO:0005886 10.23 F10 F11 F2 F3 F5 F7
15 extracellular exosome GO:0070062 10.07 F11 F2 F9 GP1BA PLAT SERPINA1

Biological processes related to Hemorrhagic Disease according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.88 F2 F5 SERPINA1 SERPINC1
2 platelet degranulation GO:0002576 9.88 F5 F8 SERPINA1 SERPINE1 SERPINF2 VWF
3 ER to Golgi vesicle-mediated transport GO:0006888 9.87 F10 F2 F5 F7 F8 F9
4 negative regulation of endopeptidase activity GO:0010951 9.84 SERPINA1 SERPINC1 SERPINE1 SERPINF2
5 negative regulation of peptidase activity GO:0010466 9.83 SERPINA1 SERPINC1 SERPINE1 SERPINF2
6 platelet activation GO:0030168 9.81 F2 F8 GP1BA VWF
7 blood coagulation GO:0007596 9.8 F10 F11 F2 F3 F5 F7
8 acute-phase response GO:0006953 9.78 F2 F8 SERPINA1 SERPINF2
9 COPII vesicle coating GO:0048208 9.75 F5 F8 SERPINA1
10 regulation of blood coagulation GO:0030193 9.73 F11 F2 GP1BA SERPINC1
11 positive regulation of blood coagulation GO:0030194 9.67 F2 F7 SERPINE1
12 negative regulation of fibrinolysis GO:0051918 9.67 F2 SERPINE1 SERPINF2 THBD
13 fibrinolysis GO:0042730 9.65 F2 GP1BA PLAT SERPINE1 SERPINF2
14 blood coagulation, extrinsic pathway GO:0007598 9.63 F10 F3 F7
15 blood coagulation, intrinsic pathway GO:0007597 9.63 F11 F2 F8 F9 GP1BA VWF
16 negative regulation of proteolysis GO:0045861 9.62 F2 PLAT
17 positive regulation of collagen biosynthetic process GO:0032967 9.62 F2 SERPINF2
18 negative regulation of blood coagulation GO:0030195 9.61 SERPINE1 THBD
19 positive regulation of positive chemotaxis GO:0050927 9.61 F3 F7
20 plasminogen activation GO:0031639 9.6 F11 PLAT
21 negative regulation of platelet activation GO:0010544 9.59 F2 THBD
22 negative regulation of plasminogen activation GO:0010757 9.57 SERPINE1 SERPINF2
23 positive regulation of platelet-derived growth factor receptor signaling pathway GO:0010641 9.55 F3 F7
24 hemostasis GO:0007599 9.44 F10 F11 F2 F3 F5 F7
25 proteolysis GO:0006508 10.03 F10 F11 F2 F7 F9 PLAT

Molecular functions related to Hemorrhagic Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptidase activity GO:0008233 9.85 F10 F11 F2 F7 F9 PLAT
2 calcium ion binding GO:0005509 9.83 F10 F2 F7 F9 THBD
3 signaling receptor binding GO:0005102 9.76 F2 F7 PLAT SERPINE1
4 peptidase inhibitor activity GO:0030414 9.71 SERPINA1 SERPINC1 SERPINE1 SERPINF2
5 serine-type peptidase activity GO:0008236 9.63 F10 F11 F2 F7 F9 PLAT
6 serine-type endopeptidase inhibitor activity GO:0004867 9.62 SERPINA1 SERPINC1 SERPINE1 SERPINF2
7 serine-type endopeptidase activity GO:0004252 9.5 F10 F11 F2 F3 F7 F9
8 protease binding GO:0002020 9.1 F3 SERPINA1 SERPINC1 SERPINE1 SERPINF2 VWF
9 protein binding GO:0005515 10.16 F10 F11 F2 F3 F5 F7

Sources for Hemorrhagic Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....